The efficacy and safety of aflibercept and conbercept in diabetic macular edema

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
dexamethasone 8 endocrinologydiseasesdrugs
diabetic retinopathy 4 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
dexamethasone 2699 Second, corticosteroid therapy, such as intravitreal injection of triamcinolone acetonide and long-acting dexamethasone implant,[5],[10]–[12] is an effective treatment modality for DME due to its anti-inflammatory functions.[13],[14]
dexamethasone 25707 intervention for DME.Comparison of aflibercept or conbercept to other drugsComparison of aflibercept to dexamethasone implantThe anti-VEGF drugs have shown superiority to laser therapy in the treatment of DME; however,
dexamethasone 26234 an observational, retrospective study was conducted recently in Spain to compare IVA vs sequential dexamethasone implant followed by IVA in naïve DME patients.[60] Fifteen patients in the IVA group were treated with
dexamethasone 26431 group were treated with aflibercept monthly for the first 5 months; whereas another 15 patients in the dexamethasone group were initially treated with a single dexamethasone implant (OZURDEX; Allergan plc, Dublin, Ireland),
dexamethasone 26488 months; whereas another 15 patients in the dexamethasone group were initially treated with a single dexamethasone implant (OZURDEX; Allergan plc, Dublin, Ireland), then both groups received IVA every 2 months. At the
dexamethasone 26751 BCVA increased from 70.8±4.1 to 83.5±2.7 letters and from 75.6±2.7 to 86.5±2.5 letters in IVA and dexamethasone groups, respectively (P=0.551). CMT decreased from 411.0±26.1 to 288.1±10.5 μm and from 411.4±24.3
dexamethasone 26898 CMT decreased from 411.0±26.1 to 288.1±10.5 μm and from 411.4±24.3 to 260.8±17.9 μm in IVA and dexamethasone groups, respectively. No statistical significance was found between the two groups in BCVA or CMT changes
dexamethasone 33833 consider especially when it is at odds with therapeutic efficacy. The sequential treatment of long-acting dexamethasone implant followed by IVA could be an option since it maintains similar efficacy as IVA alone, while reducing
Select Disease Character Offset Disease Term Instance
diabetic retinopathy 594 macular edema (DME) has shown an increasing prevalence during the past years and is the leading cause of diabetic retinopathy blindness. Traditional treatment modalities include laser and corticosteroid therapy, which, however,
diabetic retinopathy 29534 the data of this clinical trial were reanalyzed, and the effects of these three drugs on severity of diabetic retinopathy (DR) were reported.[65] After 1-year treatment, 31.2%, 22.1%, and 37.7% of the eyes with non-proliferative
diabetic retinopathy 40900 Early Treatment of Diabetic Retinopathy Study; CST, central subfield thickness; PDR, proliferative diabetic retinopathy ; NPDR, non-proliferative diabetic retinopathy; 2.0q4, 2.0 mg every 4 weeks; 1.25q4, 1.25 mg every 4
diabetic retinopathy 40946 Study; CST, central subfield thickness; PDR, proliferative diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy ; 2.0q4, 2.0 mg every 4 weeks; 1.25q4, 1.25 mg every 4 weeks; 0.5q4, 0.5 mg every 4 weeks; 0.3q4, 0.3

You must be authorized to submit a review.